COMPASS Pathways at Morgan Stanley conference: launch, data and FDA push

COMPASS Pathways expects to complete its rolling NDA submission for psilocybin-based COMP360 in Q4 2026, targeting a potential first-half 2027 U.S. launch for treatment-resistant depression (TRD). Phase III studies showed roughly a 4-point MADRS advantage versus placebo, response within 24 hours, approximately 40% response after two doses, and durability extending to 26 weeks; the company estimates a TRD market of about 4 million U.S. patients. Existing infrastructure at 8,500 SPRAVATO-certified sites could lower launch barriers, but CMPS remains pre-revenue, burns cash ($161M negative LTM free cash flow), and faces uncertain FDA, federal/state rescheduling, reimbursement and adoption timing. Shares at $14.13 have returned 171% over the past year and trade near their $15.87 52-week high, reflecting substantial launch expectations.

Analysis

CMPS has shifted from a pure clinical-risk asset toward a launch-execution asset, but the market is likely assigning too much value to regulatory velocity and too little to site-level economics. Existing esketamine sites reduce capital formation risk, yet they do not solve the binding constraint: clinician time, multi-hour room utilization, trained-session capacity, and reliable payment for that time. The early commercial KPI is therefore not site count but treated patients per activated site and gross-to-net reimbursement; a weak first 1-2 quarters would compress the premium launch multiple despite approval.

The principal near-term catalyst is NDA completion/acceptance, followed by labeling, REMS, DEA scheduling and state implementation. These are sequential rather than independent gates: a favorable FDA decision without synchronized scheduling and reimbursement can turn a nominal first-half 2027 launch into a geographically fragmented, low-volume rollout. Management's payer commentary is not evidence of coverage terms; prior authorization requirements, dose limits, and facility-payment adequacy will determine whether the lower-frequency regimen produces superior provider economics versus JNJ's SPRAVATO.

Consensus appears to view COMP360 primarily as a direct share taker from SPRAVATO. More likely, CMPS initially expands treated TRD through lower patient burden, while JNJ retains entrenched patients and benefits from further buildout of monitored psychiatry capacity. The longer-term competitive risk is that CMPS establishes the regulatory and reimbursement template that lowers barriers for later psychedelic entrants; first-mover advantage may be strongest in the first 12-24 months, not permanent. The thesis is falsified by a restrictive REMS/label, delayed scheduling, or launch metrics showing poor site activation and reimbursement despite physician interest.

Key Decisions for Investors

• Do not chase CMPS near prior highs ahead of the Q4 filing: maintain only a catalyst-sized long until NDA acceptance and label clarity. Add on a post-acceptance pullback if cash runway remains through at least the first commercial year; reduce if incremental operating-burn guidance implies pre-launch financing.
• For a 3-6 month event position, use a defined-risk CMPS call spread expiring after the expected regulatory decision rather than outright shares. The upside case is accelerated review/clean label; the maximum-loss structure protects against the non-trivial inspection, REMS, scheduling, or filing-delay tail.
• Monitor JNJ rather than shorting it: SPRAVATO persistence, center utilization, and payer behavior are the best real-world comparables for CMPS. A meaningful decline in SPRAVATO net price or provider reimbursement would be a negative read-through for CMPS economics, not automatically a CMPS share-gain signal.
• Set a launch watchlist for three metrics: activated treating sites, patients per site per month, and time to paid claim. If these are not disclosed or demonstrate slow conversion during the first two reported quarters after launch, treat that as a signal to avoid adding exposure regardless of prescription-demand commentary.